Caroline Robert
SRM Institute of Science and Technology(IN)Inserm(FR)Inserm(FR)Université Paris-Saclay(FR)Institut Gustave Roussy(FR)Assistance Publique Hôpitaux de Marseille(FR)Gunadarma University(ID)Centre Hospitalier Régional Universitaire de Brest(FR)Hôpital Sainte-Marguerite(FR)TauRx (United Kingdom)(GB)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Improved Survival with Ipilimumab in Patients with Metastatic Melanoma(2010)15,035 cited
- → Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation(2011)7,653 cited
- → PD-1 blockade induces responses by inhibiting adaptive immune resistance(2014)6,551 cited
- → Pembrolizumab versus Ipilimumab in Advanced Melanoma(2015)5,779 cited
- → Nivolumab in Previously Untreated Melanoma without BRAF Mutation(2014)5,311 cited
- → Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma(2011)4,451 cited
- →